• OP Labs formerly Oxford Peptides.
• Batch HPLC tested at 99%+ purity.
• Store frozen long term or in fridge when ready to be used.
• Sold for research purposes only.
• Contact us for Wholesale Orders.

Download COA here: ACE-031.pdf
Please note if you have a different Batch ID please contact us for the latest COA.

ACE-031 (Ramatercept)

Chemical Identity & Synonyms

• Name: ACE‑031 (also known as Ramatercept)
• Synonyms: Myostatin‑inhibitory fusion protein; ActRIIB‑Fc fusion
• CAS Number: 1621169‑52‑5 (reported in vendor listings and catalogs) :contentReference[oaicite:0]{index=0}

Molecular Structure & Composition

• Type: Recombinant fusion protein combining extracellular domain of human activin receptor type IIB (ActRIIB) with Fc region of human immunoglobulin G1 (IgG1) :contentReference[oaicite:1]{index=1}
• Formula (approx.): C₁₃₃H₂₂₇N₄₃O₃₃ :contentReference[oaicite:2]{index=2}
• Molecular Weight: ~2,956.5 Da :contentReference[oaicite:3]{index=3}
• Peptide segment: ~24 aa sequence fragment: AWRQNTRYSRIEAIKIQILSKLRL‑NH₂ :contentReference[oaicite:4]{index=4}

Biochemical & Physical Properties

• Fusion design: Extracellular ActRIIB linked to IgG1-Fc (hinge, CH2, CH3 domains) for dimeric soluble receptor format :contentReference[oaicite:5]{index=5}
• Aqueous form: Lyophilized powder, typically reconstituted in buffered saline or bacteriostatic water :contentReference[oaicite:6]{index=6}
• Pharmacokinetics: Terminal half-life ~10–15 days in humans (single ascending dose study) :contentReference[oaicite:7]{index=7}

Mechanistic Notes

• Ligand interaction: Binds myostatin, activin A, GDF11 and related TGF‑β superfamily ligands via its ActRIIB extracellular domain :contentReference[oaicite:8]{index=8}

Analytical & Quality Data

• Purity: Research-grade preparations typically ≥ 99% by HPLC (vendor-reported) :contentReference[oaicite:9]{index=9}
• Formulation: Often supplied as sterile lyophilized powder in vials; storage at –20 °C (powder) or –80 °C (reconstituted solutions) recommended :contentReference[oaicite:10]{index=10}

Safety & Research Context

• Clinical data: Phase I single-dose study in healthy volunteers reported dose-dependent linear pharmacokinetics with terminal t₁/₂ ≈10–15 days :contentReference[oaicite:11]{index=11}
• Clinical trial observations: Phase II trial in boys with Duchenne muscular dystrophy was halted due to vascular-related adverse events (e.g., epistaxis, telangiectasia) :contentReference[oaicite:12]{index=12}

📚 References (Academic Sources Only)

1. Attie KM et al. “A single ascending‑dose study of muscle regulator ACE‑031 in healthy volunteers.” Muscle & Nerve. 2013;47(3):416–423. :contentReference[oaicite:13]{index=13}
2. Campbell C et al. “Myostatin inhibitor ACE‑031 treatment of ambulatory boys with Duchenne muscular dystrophy…” Muscle Nerve. 2017;55(4):458–464. :contentReference[oaicite:14]{index=14}
3. ChemicalBook entry for ACE‑031: fusion protein description and adverse event note. :contentReference[oaicite:15]{index=15}
4. PeptideDB entry (CID, formula, sequence, MW ~2956 Da). :contentReference[oaicite:16]{index=16}
5. TargetMol catalog data: molecular formula, molecular weight, CAS and storage details. :contentReference[oaicite:17]{index=17}

Keywords: ACE-031, Ramatercept.